Facebook
X
LinkedIn
ForwardReducing Stigma: The Past, Present and Future of Recovery
Drug overdose is a huge problem facing the health care system in Kentucky. Drug overdose deaths are acute poisoning deaths due to prescription or illicit drugs. According to data from the National Center for Health Statistics, Kentucky had the second highest drug overdose death rate in the U.S. in 2013.
Kentucky Injury Prevention and Research Center - http://www.mc.uky.edu/kiprc/
Kentucky Department for Public Health http://chfs.ky.gov/dph/
Released October 2015
Healthcare professionals encounter patients seeking prescription or illicit drugs in all work settings and routinely provide 24-hour care to patients in hospital. To bring the epidemic to an end, we must ensure access to treatment for addicted patients.
Target Audience
Healthcare professionals prescribing opiates interested in reducing addiction and discovering treatment options for addicted patients.
Learning Objectives
Upon completion of this educational activity, participants will be able to:
- Define stigma and recovery
- Identify the core characteristics of a substance use disorder
- Explain how evidence-based medical treatment and recovery can improve patient, community, and public health
- Discuss how stigma may interfere with treatment goals
Faculty & Credentials
Michelle R. Lofwall, MD, DFASAM
Professor
Psychiatry and Behavioral Science
Center on Drug and Alcohol Research
University of Kentucky College of Medicine
Bell Alcohol and Addictions Chair and Medical Director
First Bridge Clinic
UK HealthCare
Lexington, Kentucky
Disclosure Information
Michelle Lofwalll, MD (planner and speaker) has relevant financial relationships with commercial interests as follows:
- Braeburn Pharmaceuticals - Consultant and Principal Investigator - Consulting Fees and Research Contract
- PCM Scientific - Speaker - Honoraria
No other planners have any relevant financial relationships to disclose.
The material presented in this course represents information obtained from the scientific literature as well as the clinical experiences of the speaker. In some cases, the presentation might include discussion of investigational agents and/or off-label indications for various agents used in clinical practice. The speaker will inform the audience when they are discussing investigational and/or off-label uses.
Content review confirmed that the content was developed in a fair, balanced manner free from commercial bias. Disclosure of a relationship is not intended to suggest or condone commercial bias in any presentation, but it is made to provide participants with information that might be of potential importance to their evaluation of a presentation.
In support of improving patient care, this activity has been planned and implemented by UK HealthCare CECentral and Kentucky Office of Drug Control Policy. University of Kentucky HealthCare CECentral is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Available Credit
- 0.75 AMA PRA Category 1 Credit™
In support of improving patient care, UK HealthCare CECentral is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), the American Nurses Credentialing Center (ANCC), and the Association of Social Work Boards (ASWB) to provide continuing education for the healthcare team.
This Enduring activity is designated for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only credit commensurate with the extent of their participation in the activity.
- 0.75 ParticipationUK Healthcare CECentral certifies this activity for 0.75 hour(s) of participation.